<DOC>
	<DOCNO>NCT00005603</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy work different way stop cancer cell divide stop grow die . Combining one chemotherapy drug may kill cancer cell . It yet know combination chemotherapy regimen effective acute lymphoblastic leukemia . PURPOSE : Phase III trial determine effectiveness combination chemotherapy treat child newly diagnose acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Combination Chemotherapy Treating Children With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether augmented BFM therapy superior ALinc 14/15 therapy patient newly diagnose high-risk acute lymphoblastic leukemia . - Determine whether minimal residual disease induction therapy predictive inferior prognosis patient population . - Determine correlation event-free survival , minimal residual disease , early response patient population treat multiple drug regimen . OUTLINE : Patients stratify CNS testicular disease ( yes v ) . - Induction therapy ( week 1-5 ) : Patients receive oral prednisone 3 time daily day 1-29 ; vincristine IV day 1 , 8 , 15 , 22 ; daunorubicin IV day 8 , 15 , 22 ; asparaginase intramuscularly ( IM ) day 2 , 5 , 8 , 12 , 15 , 19 . Patients also receive methotrexate intrathecally ( IT ) day 1 8 . Patients CNS 2 3 disease also receive methotrexate IT day 15 22 . Patients M1 bone marrow proceed consolidation therapy . Patients achieve M2 bone marrow day 29 receive oral prednisone 3 time daily day 29-42 ; vincristine IV daunorubicin IV 15 minute day 29 36 ; asparaginase IM day 29 , 32 , 36 , 39 . If bone marrow M3 day 29 M2 day 43 , patient study . - Consolidation therapy ( week 6-14 ) : Patients receive cyclophosphamide IV 30 minute day 1 29 ; cytarabine subcutaneously ( SC ) IV day 2-5 , 9-12 , 30-33 , 37-40 ; oral mercaptopurine daily day 1-14 29-42 ; vincristine IV day 15 , 22 , 43 , 50 ; asparaginase IM day 15 , 17 , 19 , 22 , 24 , 26 , 43 , 45 , 47 , 50 , 52 , 54 ; methotrexate IT day 1 , 15 , 29 , 43 . Patients proceed interim maintenance delay intensification week 15-46 . Courses repeat every 16 week . - Maintenance I II ( week 15-22 31-38 ) : Patients receive vincristine IV methotrexate IV day 1 , 11 , 21 , 31 , 41 ; asparaginase IM day 2 , 12 , 22 , 32 , 42 ; methotrexate IT day 1 31 . - Delayed Intensification ( week 23-36 39-42 ) : Patients receive vincristine IV day 57 , 64 , 71 ; methotrexate IT day 57 ; oral dexamethasone 2-3 time daily day 57-63 71-77 ; doxorubicin IV 15 minute 3 time weekly day 57 , 64 , 71 ; asparaginase IM day 60 , 62 , 64 , 67 , 69 , 71 . - Delayed Intensification-Reconsolidation ( week 27-30 43-46 ) : Patients receive oral thioguanine day 85-98 ; methotrexate IT day 85 ; cyclophosphamide IV 30 minute day 85 ; cytarabine IV SC day 86-89 93-96 ; asparaginase IM day 99 , 101 , 103 , 106 , 108 , 110 ; vincristine IV day 99 106 . - Continuation therapy ( week 47-130 ) : Patients receive vincristine IV day 1 , 29 , 57 ; oral dexamethasone twice daily 5 consecutive day day 1-5 , 29-33 , 57-61 ; oral mercaptopurine day 1-84 ; oral methotrexate day 8 , 15 , 22 , 29 , 36 , 43 , 50 , 57 , 64 , 71 , 78 ; methotrexate IT day 1 . Patients CNS 3 disease within 24 month diagnosis initial WBC â‰¥ 100,000/mm^3 undergo whole brain radiotherapy ( omit discontinue mercaptopurine IT methotrexate ) day 1 . Testicular radiotherapy also begin day 1 . Patients may receive oral methotrexate day 1 course ( IT methotrexate administer ) . Patients follow every 2 month 2 year , every 3 month 1 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 260 patient accrue study within 3.1 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Thioguanine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Bcell precursor acute lymphoblastic leukemia Registered POG9900 Classification Study Registered within 7 day document complete response induction day 29 , 2 week induction require , later day 49 Classified high risk : No simultaneous trisomy 4 10 No TELAML1 gene Meets criteria 1 following : Any age WBC &gt; 100,000/mm^3 CNS bone marrow evaluation require patient WBC &gt; 100,000/mm^3 within 24 month initial diagnosis Age 12 ( boy ) 16 ( girl ) If young , WBC must 1 following : Greater 80,000/mm^3 ( boys age 8 girl age 12 ) Greater 60,000/mm^3 ( boys age 9 girl age 13 ) Greater 40,000/mm^3 ( boys age 10 girl age 14 ) Greater 20,000/mm^3 ( boys age 11 girl age 15 ) At least one following : CNS 3 disease ( CSF WBC least 5/microliter blast present ) Testicular leukemia MLL gene rearrangement PATIENT CHARACTERISTICS : Age : 1 21 Performance status : Not specify Life expectancy : Not specify Hematopoietic : See Disease Characteristics Hepatic : Not specify Renal : Not specify Other : Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify Other : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>childhood acute lymphoblastic leukemia remission</keyword>
	<keyword>B-cell childhood acute lymphoblastic leukemia</keyword>
</DOC>